Authors:
Amanda Smith, PharmD
Nicole Slater, PharmD, BCACP
Reviewers:
Vivian Cheng, PharmD, BCPS, BCACP
Joseph Nardolillo, PharmD, BCACP
Citation:
Choi JG, Winn AN, Skandari MR, et al. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study. Ann Intern Med. 2022;175(10):1392-1400.
The Problem
You must be logged in to post a comment.
Top Ten Things Every Clinician Should Know About the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Deintensifying Glycemic Goals and Treatment Regimens in Older Adults
Prescription for Savings: The Clinical and Economic Impact of Pharmacist-Led Hypertension Management in the U.S.
Making the GRADE: Durability of Glycemic Response in Type 2 Diabetes
Defining the Role of Semaglutide in Obese Patients with Heart Failure with Preserved Ejection Fraction
Can Losing Weight Using Semaglutide Prevent a Heart Attack, Ack, Ack, Ack, Ack?
iForumRx.org is a web-based community of practice designed to inform ambulatory care pharmacy specialists, pharmacy residents, and student pharmacists about high-quality, practice-changing evidence.
Loading ...
Are there any data on an anti-cancer effect with the newer agents (as exist for Metformin)?